Research ArticleFeatured Articles

Multifactorial Approach to the Primary and Secondary Prevention of Atherosclerosis

Carl J. Lavie and Richard V. Milani
Ochsner Journal December 2003, 5 (1) 12-17;

REFERENCES

  1. ↵
    1. Milani R. V.,
    2. Lavie C. J.,
    3. Gilliland Y. E.
    (2002) Overview of transesophageal echocardiography for the chest physician. Chest, in press.
  2. ↵
    1. Smith S. C. Jr.,
    2. Greenland P.,
    3. Grundy S. M.
    (2000) AHA Conference Proceedings. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: executive summary. American Heart Association. Circulation 101:111–116, pmid:10618313.
    OpenUrlFREE Full Text
    1. National Heart, Lung, and Blood Institute
    (2001) Fact Book Fiscal Year 2000. Bethesda, MD: National Institutes of Health.
  4. ↵
    1. Milani R. V.,
    2. Lavie C. J.
    (1999) Smoking cessation: the importance of medical intervention. Ochsner Journal 1:141–144, pmid:21845132.
    OpenUrlFREE Full Text
  5. ↵
    1. U.S. Department of Health and Human Services
    (2000) Clinical Practice Guideline: Treating tobacco use and dependence. Washington, D.C.: U.S. Department of Health and Human Services.
  6. ↵
    1. American Heart Association
    (2000) 2001 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association.
    1. Carretero O. A.,
    2. Oparil S.
    (2000) Essential hypertension: Part II: Treatment. Circulation 101:446–453, pmid:10653838.
    OpenUrlFREE Full Text
    1. National Heart, Lung, and Blood Institute
    (1997) The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: National Institutes of Health.
  9. ↵
    1. Lavie C. J.,
    2. Ventura H. O.,
    3. Messerli F. H.
    (1991) Regression of increased left ventricular mass by antihypertensives. Drugs 42:945–961, pmid:1724641.
    OpenUrlPubMedWeb of Science
  10. ↵
    1. Lavie C. J.,
    2. Milani R. V.,
    3. Mehra M. R.
    Hypertension and left ventricular hypertrophy in the elderly, 109–127, In: Tresch DD, Aronow WS (eds). Cardiovascular Disease in the Elderly Patient, ed 2. New York, NY, and Basel, Switzerland: Marcel Dekker, 1999. Chapter 6, pp.
  11. ↵
    1. Yusuf S.,
    2. Sleight P.,
    3. Pogue J.
    (2000) The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145–153, pmid:10639539.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. O'Keefe J. H.,
    2. Wetzel M.,
    3. Moe R. R.,
    4. Bronsnahan K.,
    5. Lavie C. J.
    (2001) Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? J Am Coll Cardiol 37:1–8, pmid:11153722.
    OpenUrlFREE Full Text
  13. ↵
    1. Lindholm L. H.,
    2. Ibsen H.,
    3. Dahlof B.
    (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:1004–1010, pmid:11937179.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Lavie C. J.,
    2. Gau G. T.,
    3. Squires R. W.
    (1988) Management of lipids in primary and secondary prevention of cardiovascular diseases. Mayo Clin Proc 63:605–621, pmid:3287024.
    OpenUrlPubMedWeb of Science
    1. Lavie C. J.,
    2. O'Keefe J. H.,
    3. Blonde L.
    (1990) High-density lipoprotein cholesterol. Recommendations for routine testing and treatment. Postgrad Med 87:36–44, 47, 51, pmid:2188240.
    OpenUrlPubMed
    1. Lavie C. J.,
    2. Milani R. V.
    (1996) Effects of nonpharmacologic therapy with cardiac rehabilitation and exercise training in patients with low levels of high-density lipoprotein cholesterol. Am J Cardiol 78:1286–1289, pmid:8960593.
    OpenUrlCrossRefPubMedWeb of Science
    1. Lavie C. J.,
    2. Milani R. V.
    (1994) Effects of cardiac rehabilitation and exercise training on low-density lipoprotein cholesterol in patients with hypertriglyceridemia and coronary artery disease. Am J Cardiol 74:1192–1195, pmid:7977088.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Ross S. D.,
    2. Allen I. E.,
    3. Connelly J. E.
    (1999) Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 159:1793–1802, pmid:10448784.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Byington R. P.,
    2. Davis B. R.,
    3. Plehn J. F.
    (2001) Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 103:387–392, pmid:11157690.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Waters D.,
    2. Schwartz G. G.,
    3. Olsson A. G.
    (2001) Stroke reduction with atorvastatin in acute coronary syndromes: results of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial (abstract). Circulation 104:II529–530.
    OpenUrl
  21. ↵
    (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22, pmid:12114036.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. American Diabetes Association: clinical practice recommendations 1997
    (1997) Diabetes Care 20(Suppl 1):S1–70, pmid:9028710.
    OpenUrlFREE Full Text
  23. ↵
    1. Davis P. H.,
    2. Dambrosia J. M.,
    3. Schoenberg B. S.
    (1987) Risk factors for ischemic stroke: a prospective study in Rochester, Minnesota. Ann Neurol 22:319–327, pmid:3674797.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486–2497, pmid:11368702.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Milani R. V.,
    2. Lavie C. J.
    (2002) Prevalence and effects of cardiac rehabilitation in CHD patients with metabolic syndrome (abstract). Circulation 105(19):II–712.
    OpenUrl
  26. ↵
    1. Lavie C. J.,
    2. Milani R.,
    3. Mehra M. R.
    (2002) Obesity, weight reduction, and survival in heart failure. J Am Coll Cardiol 39:1563–1564, pmid:11985924.
    OpenUrlFREE Full Text
    1. Lavie C. J.,
    2. Milani R. V.,
    3. Messerli F. H.
    (2002) Obesity and the heart – an ever growing problem. South Med J, in press.
    1. Lavie C. J.,
    2. Milani R. V.,
    3. Messerli F. H.
    (2000) From obesity, hypertension, and left ventricular hypertrophy to congestive heart failure. Ochsner Journal 2((Supplement 1)):S8–S14.
    OpenUrl
  29. ↵
    1. Lavie C. J.,
    2. Milani R. V.
    (1997) Effects of cardiac rehabilitation, exercise training, and weight reduction on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in obese coronary patients. Am J Cardiol 79:397–401, pmid:9052338.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Lavie C. J.,
    2. Milani R. V.,
    3. Morchedi A.
    (2003) Impact of obesity on inflammation and metabolic syndrome in coronary patients and effects of cardiac rehabilitation (abstract). J Am Coll Cardiol, in press.
  31. ↵
    1. Mokdad A. H.,
    2. Serdula M. K.,
    3. Dietz W. H.
    (2000) The continuing epidemic of obesity in the United States. JAMA 284:1650–1651, pmid:11015792.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    1. Williamson D. F.,
    2. Pamuk E.,
    3. Thun M.
    (1995) Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40–64 years. Am J Epidemiol 141:1128–1141, pmid:7771451.
    OpenUrlPubMedWeb of Science
  33. ↵
    1. Lavie C. J.,
    2. Milani R. V.,
    3. Marks P.
    (2001) Exercise and the heart: Risks, benefits, and recommendations for providing exercise prescriptions. Ochsner Journal 3:207–212, pmid:21765739.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Ridker P. M.,
    2. Rifai N.,
    3. Rose L.
    (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557–1565, pmid:12432042.
    OpenUrlCrossRefPubMedWeb of Science
  35. ↵
    1. Ali A.,
    2. Mehra M. R.,
    3. Lavie C. J.
    (1998) Modulatory impact of cardiac rehabilitation on hyperhomocysteinemia in patients with coronary artery disease and “normal” lipid levels. Am J Cardiol 82:1543–5, A8, pmid:9874065.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Lavie C. J.,
    2. Milani R. V.,
    3. O'Keefe J. H.
    (1996) Update on new coronary risk factors (Editorial). Chest 110:583–584, pmid:8797390.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015–2022, pmid:12387654.
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Danesh J.,
    2. Collins R.,
    3. Peto R.
    (2000) Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102:1082–1085, pmid:10973834.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Lavie C. J.,
    2. Milani R. V.
    Lipid lowering drugs: nicotinic acid, 1061–1067, In: Messerli FH (ed). Cardiovascular Drug Therapy, 2nd edition. Philadelphia: W. B. Saunders Company, 1996. Chapter 114, pp.
  40. ↵
    1. Grady D.,
    2. Herrington D.,
    3. Bittner V.
    (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:49–57, pmid:12090862.
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    1. Pradhan A. D.,
    2. Manson J. E.,
    3. Rossouw J. E.
    (2002) Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 288:980–987, pmid:12190368.
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    1. Lavie C. J.,
    2. Mailander L.,
    3. Milani R. V.
    (1992) Marked benefit with sustained-release niacin therapy in patients with “isolated” very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol 69:1083–1085, pmid:1561983.
    OpenUrlCrossRefPubMedWeb of Science
  43. ↵
    1. Milani R. V.,
    2. Lavie C. J.,
    3. Cassidy M. M.
    (1996) Effects of cardiac rehabilitation and exercise training programs on depression in patients after major coronary events. Am Heart J 132:726–732, pmid:8831359.
    OpenUrlCrossRefPubMedWeb of Science
    1. Lavie C. J.,
    2. Milani R. V.
    (1999) Effects of cardiac rehabilitation and exercise training programs on coronary patients with high levels of hostility. Mayo Clin Proc 74:959–966, pmid:10918860.
    OpenUrlCrossRefPubMedWeb of Science
    1. Lavie C. J.,
    2. Milani R. V.
    (1999) Cardiac rehabilitation programs markedly improve high-risk profiles in coronary patients with high pshcyological distress (abstract). Circulation 100:I–825.
    OpenUrl
    1. Lavie C. J.,
    2. Milani R. V.,
    3. DeGruiter H.
    (2003) High prevalence of anxiety in coronary patients with marked improvements following cardiac rehabilitation (abstract). J Am Coll Cardiol, in press.
  47. ↵
    1. Straus S. E.,
    2. Majumdar S. R.,
    3. McAlister F. A.
    (2002) New evidence for stroke prevention; scientific review. JAMA 288:1388–1395, pmid:12234233.
    OpenUrlCrossRefPubMedWeb of Science
  48. ↵
    1. Lavie C. J.,
    2. Genton E.
    (1991) Hemostasis, thrombosis, and antiplatelet therapy - implications for the prevention of cardiovascular diseases. Cardiovascular Reviews and Reports 12:24–47.
    OpenUrl
  49. ↵
    1. Weisman S. M.,
    2. Graham D. Y.
    (2002) Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 162:2197–2202, pmid:12390062.
    OpenUrlCrossRefPubMedWeb of Science
  50. ↵
    (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348:1329–1339, pmid:8918275.
    OpenUrlCrossRefPubMedWeb of Science
  51. ↵
    1. Yusuf S.,
    2. Zhao F.,
    3. Mehta S. R.
    (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502, pmid:11519503.
    OpenUrlCrossRefPubMedWeb of Science
  52. ↵
    1. Gaspoz J. M.,
    2. Coxson P. G.,
    3. Goldman P. A.
    (2002) Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 346:1800–1806, pmid:12050341.
    OpenUrlCrossRefPubMedWeb of Science
  53. ↵
    1. Lavie C. J.,
    2. Squires R. W.,
    3. Gau G. T.
    (1987) Preventive cardiology - what is the role of fish and fish oils in primary and secondary prevention. J Cardiopulm Rehab 7:526–533.
    OpenUrl
  54. ↵
    1. Lavie C. J.,
    2. Milani R. V.
    (1996) Fish Oils, 1608–1613, In: Messerli FH (ed). Cardiovascular Drug Therapy, 2nd edition. Philadelphia: W. B. Saunders Company, Chapter 174.
  55. ↵
    1. Alaswad K.,
    2. Lavie C. J.,
    3. Milani R. V.
    (2002) Fish oil in cardiovascular prevention. Ochsner Journal 4:83–91.
    OpenUrl
  56. ↵
    1. He K.,
    2. Rimm E. B.,
    3. Merchant A.
    (2002) Fish consumption and risk of stroke in men. JAMA 288:3130–3136, pmid:12495393.
    OpenUrlCrossRefPubMedWeb of Science
  57. ↵
    1. Milani R. V.,
    2. Lavie C. J.,
    3. Brewer G.,
    4. Mehra M. R.
    (2001) Reduction in hs-CRP in coronary patients with exercise training and diet. Circulation 104(17):II–414.
    OpenUrl
  58. ↵
    1. Lavie C. J.,
    2. Milani R. V.,
    3. Cassidy M. M.
    (1999) Cardiopulmonary rehabilitation, exercise training and preventive cardiology: an overview of a decade of research at the Ochsner Heart and Vascular Institute. Ochsner Journal 1:177–186, pmid:21845136.
    OpenUrlAbstract/FREE Full Text
  59. ↵
    1. Church T. S.,
    2. Lavie C. J.,
    3. Milani R. V.
    (2000) Improvements in blood rheology after cardiac rehabilitation and exercise training in patients with coronary heart disease. Am Heart J 143:349–355, pmid:11835042.
    OpenUrlPubMed
  60. ↵
    1. Lucini D.,
    2. Milani R. V.,
    3. Costantino G.
    (2002) Effects of cardiac rehabilitation and exercise training on autonomic regulation in patients with coronary artery disease. Am Heart J 143:977–983, pmid:12075252.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section